ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Personal letters: mixed reviews of Donald Pinkel’s article on Childhood Lymphocytic Leukemia

May 6, 2021

Panel Says Tamoxifen Remains Standard for Preventing Breast Cancer

May 24, 2002

Broder Says No Thanks To Acknowledgement For Paper’s Title

June 6, 1997

Program Project Guidelines Available

October 27, 1995

Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%

February 25, 2011

Elias Zerhouni Nominated for NIH Director; Richard Carmona For Surgeon General

April 5, 2002